Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 102 systematic review(s)/meta-analysis(es). 2. mRNA-1273 (Spikevax) in Immunocompromised (IC) Individuals: Reduced risk of SARS-CoV-2 infection (risk ratio (RR) 0.85 [95% confidence interval (CI): 0.75-0.97]) and severe disease (RR 0.85 [95% CI: 0.77-0.93]) compared to BNT162b2. Hospitalization risk also decreased (RR 0.88 [95% CI: 0.79-0.97]). ^[1-102]
• Heterologous Booster for mRNA-1273: Showed high effectiveness against COVID-19 infection (89.19% [95% CI: 78.49-99.89]) and severe disease (69.99% [95% CI: 52.16-87.82]).
• Seroconversion in Lung Transplant Recipients: Overall rate was 72%, with lower rates in the leukopenia group (59%) and higher rates in recipients >7 years post-transplant (83%).
• Mortality in IC Populations: COVID-19-related mortality was significantly reduced with mRNA-1273 (RR 0.63 [95% CI: 0.44-0.90]).
• Lung Transplant Recipients (LTR): Adverse events were reported in 18% of individuals, with the most common being pain at the injection site and fatigue. No severe adverse events were noted.
• Patients with Plasma Cell Dyscrasia: There were no severe adverse events reported in this population, despite lower seroconversion rates linked to older age and active therapy.
• Systemic Lupus Erythematosus (SLE) Patients: Adverse events, including lupus flares, were infrequent. Severe adverse events were rare.
• Myocarditis and Pericarditis: These adverse events were more common in younger males, typically after the second dose of mRNA vaccines.
• In immunocompromised populations, mRNA-1273 demonstrated improved clinical effectiveness compared to BNT162b2, while a higher incidence of adverse events was observed, particularly in those undergoing immunosuppressive treatments, with certain subgroups experiencing lower seroconversion rates (e.g., leukemia patients).
• Lung transplant recipients showed significant variation in seroconversion rates influenced by factors such as body mass index (BMI), leukopenia, post-transplant time, and type of immunosuppressants, with no major safety concerns beyond mild adverse events.